Response to pegintin HBeAg-ve : On-treatment kinetics of qHBsAg vary by genotype
Response to peginterferon alfa-2a (40KD) in HBeAg-negative CHB: On-treatment kinetics of HBsAg serum levels vary by HBV genotype
Maurizia R. Brunettoa, Corresponding author contact information, E-mail the corresponding author,
Stephanos J. Hadziyannise,
a U.O. Epatologia–Azienda Ospedaliero Universitaria Pisana, Pisa, Italy
b Service d’Hépatologie and Centre de Recherches Biologiques Beaujon, University of Paris, Clichy, France
c Department of Gastroenterology, University of Ankara Medical School, Ankara, Turkey
d Department of Medical Sciences, University of Cagliari, Cagliari, Italy
e Department of Medicine and Hepatology, Henry Dunant Hospital and Liver Research Unit of Athens University at Evgenidio Hospital Athens, Greece
f IST GmbH, Mannheim, Germany
g F. Hoffmann-La Roche, Basel, Switzerland
h Cattedra di Gastroenterologia – Università Pisa, Italy
Background & aims
We investigated whether HBV genotype influences on-treatment HBsAg kinetics and/or the end-of-treatment HBsAg levels associated with long-term virological response in HBeAg-negative chronic hepatitis B patients treated with peginterferon alfa-2a ± lamivudine in the Phase III trial.
All patients (n = 230) who participated in long-term follow-up were included according to the availability of HBsAg levels measurements. Long-term virological response was defined as HBV DNA ⩽10,000 cp/mL (1786 IU/mL) at 5 years post-treatment. Genotype-specific end-of-treatment HBsAg levels associated with long-term virological response (identified by ROC analysis) were assessed in 199 patients with HBsAg measurements available at baseline and end-of-treatment. HBsAg kinetics according to genotype and long-term virological response were investigated in the 117 patients with additional samples available at weeks 12, 24 and 72.
Baseline HBsAg levels were significantly higher for A than B, C and D genotypes (p<0.05). On-treatment HBsAg kinetics varied according to HBV genotype. The difference between responders and non-responders was greatest for genotype A from weeks 12 to 24; for genotypes B and D from baseline to week 12; there was no significant difference over any timeframe for genotype C. High positive predictive values for long-term virological response could be obtained by applying end-of-treatment genotype-specific cut-offs: 75%, 47%, 71% and 75% for genotypes A (<400 IU/mL), B (<50 IU/mL), C (<75 IU/mL) and D (<1000 IU/mL), respectively.
On-treatment HBsAg kinetics vary between HBV genotypes. Genotype-specific monitoring timeframes and end-of-treatment thresholds could ameliorate response-guided treatment of HBeAg-negative chronic hepatitis B.
The abstract is very brief.
"High positive predictive values for long-term virological response could be obtained by applying end-of-treatment genotype-specific cut-offs: 75%, 47%, 71% and 75% for genotypes A (<400 IU/mL), B (<50 IU/mL), C (<75 IU/mL) and D (<1000 IU/mL), respectively. "
Maybe someone can provide access to the full paper or provide more information. It seems that Genotypes B and C require really low end-of-treatment qHBsAg to achieve long-term response?
This study is not informative enough. There is really not enough information about genotype's HBSAg levels. As Steff saids Genotype B needs <100iu/ml HBSAG and HEP B DNA <2000iu/ml to be true inactive carrier. Other types like genotype D have high HBSAG to be carrier.
Nucs have a place. It allows sequential treatment. If you fail peg your can keep nucs. Then try PEG again in a couple of years. Not every one will repond to PEG. Tenofovir can give the body a break from fighting and allow immune recovery.
The Content on this Site is presented in a summary fashion, and is intended to be used for educational and entertainment purposes only. It is not intended to be and should not be interpreted as medical advice or a diagnosis of any health or fitness problem, condition or disease; or a recommendation for a specific test, doctor, care provider, procedure, treatment plan, product, or course of action. Med Help International, Inc. is not a medical or healthcare provider and your use of this Site does not create a doctor / patient relationship. We disclaim all responsibility for the professional qualifications and licensing of, and services provided by, any physician or other health providers posting on or otherwise referred to on this Site and/or any Third Party Site. Never disregard the medical advice of your physician or health professional, or delay in seeking such advice, because of something you read on this Site. We offer this Site AS IS and without any warranties. By using this Site you agree to the following Terms and Conditions. If you think you may have a medical emergency, call your physician or 911 immediately.